DECIPHER LABS LIMITED

BSE: DECIPHER524752ISIN INE643N01012

Healthcare
Pharmaceuticals

Share price

₹5.30-0.10 (-1.85%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹10.99
52W low: ₹4.81
Off 52W high: -51.77%
1M return: -6.53%
3M return: -13.11%
6M return: -31.79%
1Y return: -46.08%
20D avg volume: 3,933
50 DMA: ₹5.66
200 DMA: ₹6.69

Key ratios Consolidated

Market cap: ₹5.35 Cr
Current price: ₹5.30
52W high / low: ₹10.99 / ₹4.81
Face value: ₹10.00
P/E: -1.75
P/B: 0.65
EPS (TTM): ₹-3.03
Book value / share: ₹8.16
ROE: —
ROCE: -44.60%
Operating margin: —
Net margin: —
Debt / equity: 0.06
Net debt: ₹0.47 Cr
Interest cover: —
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: -1.8 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	2.41	3.60	3.21	4.31	2.92	3.50	5.80	5.87	7.44	—
	0.10	0.17	0.02	0.02	0.01	0.87	0.17	0.12	0.16	—
	2.51	3.78	3.23	4.33	2.94	4.37	5.97	5.99	7.60	—
	4.70	3.53	3.76	4.32	6.36	10.20	6.56	7.32	6.24	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	0.00	0.00	0.00	0.00	0.64	0.23	0.15	—	0.29	—
	2.76	2.68	3.54	4.05	4.73	3.76	5.83	6.69	5.11	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	0.13	0.15	0.13	0.13	0.12	0.13	0.12	0.12	0.11	—
	1.80	0.70	0.10	0.14	0.87	6.08	0.46	0.51	0.72	—
	-2.19	0.25	-0.53	0.02	-3.42	-5.83	-0.58	-1.33	1.36	—
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	-2.19	0.25	-0.53	0.02	-3.42	-5.83	-0.58	-1.33	1.36	—
	0.00	0.61	0.01	0.00	0.00	-1.73	0.01	0.00	0.41	—
	-2.19	-0.36	-0.54	0.02	-3.43	-4.11	-0.59	-1.33	0.95	—
	-2.16	-0.35	-0.53	0.02	-3.39	-4.07	-0.59	-1.31	0.94	—
Key metrics
	-2.06	0.40	-0.40	0.15	-3.30	-5.70	-0.46	-1.21	1.47	—
	-85.50%	11.10%	-12.50%	3.50%	-113.00%	-162.90%	-7.90%	-20.60%	19.80%	—
	-90.90%	-10.00%	-16.80%	0.50%	-117.50%	-117.40%	-10.20%	-22.70%	12.80%	—
	—	3.00%	—	0.10%	—	-25.50%	—	—	—	—
	-17.50%	2.90%	-44.70%	-26.60%	-60.80%	—	—	—	—	—
	36.20%	91.20%	8.50%	101.50%	-461.10%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	13.53	14.05	22.61	—
	0.31	0.22	1.32	—
	13.85	14.28	23.93	—
	16.31	17.96	30.32	—
	0.00	0.00	0.00	—
	0.00	0.65	0.67	—
	13.03	14.99	21.39	—
	0.00	0.00	0.00	—
	0.54	0.52	0.48	—
	2.74	1.82	7.78	—
	-2.45	-3.69	-6.39	—
	0.00	0.00	0.00	—
	-2.45	-3.68	-6.39	—
	0.62	-0.60	-1.31	—
	-3.07	-3.08	-5.08	—
	-3.02	-3.05	-5.03	—
Key metrics
	-1.91	-3.16	-5.91	—
	-14.12%	-22.50%	-26.10%	—
	-22.69%	-21.90%	-22.50%	—
	—	-44.60%	-28.00%	—
	-25.21%	-37.90%	—	—
	—	39.40%	—	—
	—	-2.32	-9.88	—
	—	0.68	1.93	—
	—	0.06	0.01	—
	—	0.47	-2.57	—
	—	-1.8	49.4	—
Balance sheet
	—	9.00	25.76	—
	—	0.17	21.05	—
	—	0.03	2.81	—
	—	0.03	4.22	—
	—	0.00	0.00	—
	—	0.10	12.01	—
	—	0.12	0.83	—
	—	0.10	1.16	—
	—	0.75	2.91	—
	—	0.50	0.24	—
	—	0.50	0.24	—
	—	0.00	0.00	—
	—	8.24	22.86	—
Cash flow
	—	-2.08	-9.82	—
	—	-0.24	3.07	—
	—	0.26	0.24	—
	—	0.24	0.06	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	0.10	0.07	0.13	0.09	0.85	0.23	0.16	0.08	0.38	—
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00	—
	0.10	0.07	0.13	0.09	0.85	0.23	0.16	0.10	0.39	—
	0.18	0.24	0.14	0.20	0.79	0.39	0.25	0.16	0.51	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	0.00	0.00	0.00	0.00	0.64	0.23	0.15	—	0.29	—
	0.05	0.05	0.05	0.04	0.04	0.08	0.03	0.04	0.08	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	0.11	0.18	0.09	0.16	0.10	0.07	0.07	0.11	0.14	—
	-0.08	-0.17	-0.01	-0.12	0.06	-0.16	-0.09	-0.06	-0.13	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	-0.08	-0.17	-0.01	-0.12	0.06	-0.16	-0.09	-0.06	-0.13	—
	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.01	—
	-0.08	-0.17	-0.01	-0.12	0.06	-0.17	-0.09	-0.06	-0.13	—
	-0.08	-0.17	-0.01	-0.11	0.06	-0.17	-0.09	-0.06	-0.13	—
Key metrics
	-0.08	-0.17	-0.01	-0.12	0.06	-0.16	-0.09	-0.06	-0.13	—
	-80.00%	-242.90%	-7.70%	-133.30%	7.10%	-69.60%	-56.20%	-75.00%	-34.20%	—
	-80.00%	-242.90%	-7.70%	-133.30%	7.10%	-73.90%	-56.20%	-75.00%	-34.20%	—
	—	-2.10%	—	-1.40%	—	-1.90%	—	—	—	—
	-88.20%	-69.60%	-18.80%	12.50%	123.70%	—	—	—	—	—
	-233.30%	0.00%	88.90%	-100.00%	146.20%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	0.39	1.14	0.85	—
	0.00	0.00	0.02	—
	0.39	1.14	0.88	—
	0.76	1.38	1.31	—
	0.00	0.00	0.00	—
	0.00	0.65	0.67	—
	0.19	0.18	0.23	—
	0.00	0.00	0.00	—
	0.00	0.02	0.02	—
	0.54	0.54	0.39	—
	-0.38	-0.24	-0.44	—
	0.00	0.00	0.00	—
	-0.38	-0.24	-0.44	—
	0.01	0.01	0.00	—
	-0.38	-0.25	-0.44	—
	-0.37	-0.24	-0.44	—
Key metrics
	-0.38	-0.22	-0.42	—
	-97.44%	-19.30%	-49.40%	—
	-97.44%	-21.90%	-51.80%	—
	—	-2.90%	-5.20%	—
	-70.45%	34.10%	—	—
	—	43.20%	—	—
	—	-0.29	0.01	—
	—	1.16	-0.16	—
	—	0.06	0.03	—
	—	0.47	0.19	—
	—	-22.4	-4.3	—
Balance sheet
	—	9.00	9.18	—
	—	0.17	0.32	—
	—	0.03	0.05	—
	—	0.03	0.23	—
	—	0.00	0.00	—
	—	0.10	0.04	—
	—	0.12	0.14	—
	—	0.10	0.24	—
	—	0.75	0.69	—
	—	0.50	0.24	—
	—	0.50	0.24	—
	—	0.00	0.00	—
	—	8.24	8.49	—
Cash flow
	—	-0.29	0.07	—
	—	0.00	-0.05	—
	—	0.26	0.00	—
	—	0.00	0.06	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): -70.45%
Profit YoY (TTM): -46.15%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): -25.21%
Profit YoY (TTM): +67.55%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 16.43%

Quarter	September 2026	June 2026
Promoter %	16.43%	16.43%

Holder	Type	Holding	Previous	Change
AJJARAPU JANAKIRAM	Promoter	16.43%	16.43%	0.00%
SESHU SRINIVAS AKULA	Public	3.80%	3.80%	0.00%
SUSHANT MOHAN LAL	Public	2.14%	2.14%	0.00%
SURIADOSS ELUMALAI	Public	1.42%	1.42%	0.00%
SHRI KRISHNA MAHESHWARI (HUF)	Public	1.37%	1.37%	0.00%
CYRIL SEBASTIAN	Public	1.17%	1.20%	-0.03%
SUMAN CHEPURI	Public	1.09%	1.05%	+0.04%
Bank Foreign	Public	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
DECIPHER LABS LIMITED	5	5.30	-1.75	-44.60%	-25.21% TTM	+67.55% TTM	-46.08%

Filings & corporate actions

Recent announcements

Certificate under Regulation 74(5) of SEBI(DP) Regulations, 2018.14 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Voting Results and Scrutinizer''s Report for 40th Annual General Meeting held on 30th September, 2026 at 11:00 AM.30 Sep 2026 · AGM/EGM / AGM
Outcome and Proceedings of 40th Annual General Meeting held on 30th September, 2026 at 11:00 AM.30 Sep 2026 · AGM/EGM / AGM
Closure of trading window for the period ending on 30.09.2026.29 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper Advertisement for the Annual General Meeting to be held for the FY_2025-26.9 Sep 2026 · Company Update / General
Intimation of Book Closure date and Cut Off Date for Annual General Meeting scheduled to be held on 30th September, 2026.8 Sep 2026 · AGM/EGM / AGM
40th Annual Report for the Financial Year 2025-268 Sep 2026 · Others / Reg. 34 (1) Annual Report
Notice of the 40th Annual General Meting for the Financial Year 2025-26 under regulation 34 of SEBI (LODR), Regulations 2015.8 Sep 2026 · AGM/EGM / AGM
Appointment of Auditors and resignation of Independent Director of the Company.5 Sep 2026 · Company Update / Change in Management
Outcome of Board Meeting held on 05.09.2026.5 Sep 2026 · Others / Outcome without intimation
Announcement under Regulation 30 of SEBI (Listng Obligations and Disclosure Requirement), Regulations, 2015.14 Aug 2026 · Company Update / General
Revised Un-audited Financial Results for the quarter ended 30.06.2026.13 Aug 2026 · Result / Financial Results
Appointment of Mr. Bhupendralal Waghray as an Additional Director (Independent Category) of the company for a period of Five (5) years w.e.f. 13.08.2026 subject to approval of shareholders.13 Aug 2026 · Company Update / Change in Directorate
Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30.06.2026.13 Aug 2026 · Result / Financial Results
Outcome of Board Meeting held on 13th August, 2026.13 Aug 2026 · Board Meeting / Outcome of Board Meeting
Decipher Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve 1. Un-audited financial results ....6 Aug 2026 · Board Meeting / Board Meeting
Compliance as per Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30.06.202616 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of trading window for the period ending 30th June, 202624 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Annual secretarial Compliance report30 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Audited standalone and consolidated financial results & statements for the quarter and year ended 31.03.202630 May 2026 · Result / Financial Results
Outcome of the Board Meeting held on 30.05.202630 May 2026 · Board Meeting / Outcome of Board Meeting
Decipher Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve 1. Audited Financial results ....26 May 2026 · Board Meeting / Board Meeting
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''> <tr> <td>Sr. No.</td> <td>Particulars</td> ....22 Apr 2026 · Others / Format of the Annual Disclosure to be made by an entity identified as a LC : Annexure B2
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....21 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Compliance as per Regulation 74 (5) of SEBI (Depositories And Participants) Regulation ,2018 for the quarter ended 31st March 202617 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window for the period ending on 31st March, 2026.24 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Unaudited Financial Results for the quarter and nine months ended 31.12.2025.12 Feb 2026 · Result / Financial Results
Outcome of Board Meeting held on Thursday, 12th February, 2026.12 Feb 2026 · Board Meeting / Outcome of Board Meeting
Scrutinizer''s Report for the Extra-ordinary General meeting held on 12.02.2026.12 Feb 2026 · AGM/EGM / EGM
Outcome of the Extra-ordinary General Meeting held on 12.02.2026.12 Feb 2026 · AGM/EGM / EGM
Decipher Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve 1. Un-audited financial results ....9 Feb 2026 · Board Meeting / Board Meeting
EGM will be held on 12.02.202621 Jan 2026 · AGM/EGM / EGM
Outcome of the Board meeting held on 19.01.202619 Jan 2026 · Others / Outcome without intimation
Complaince as per Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December, 2025.13 Jan 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 for the period ending on December 31, 2025.29 Dec 2025 · Insider Trading / SAST / Closure of Trading Window
Appointment of Mr. Dalavath Amar Singh as Additional Director ( Executive Category) of the Company13 Nov 2025 · Company Update / Change in Management
Unaudited financial results for the quarter and half year ended 30.09.202513 Nov 2025 · Result / Financial Results
Outcome of the Board Meeting held on 13.11.202513 Nov 2025 · Board Meeting / Outcome of Board Meeting
Decipher Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve 1. Un-audited financial results ....10 Nov 2025 · Board Meeting / Board Meeting
Compliance as per Reg 74(5) of SEBI (Depositories and Participants), Regulations, 2018 for the Quarter ended 30th September, 202518 Oct 2025 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Board meetings

13 Aug 2026 Board Meeting - Financial Results